BioLine RxFRA:YP2 +3.97%21 3-Year RORE % is 0.00 as of Mar. 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 1,288 Biotechnology companies, BioLine Rx ranks worse than 77639.67% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
BioLine Rx's 3-Year RORE % for the quarter that ended in Mar. 2026 was 0.00%.
The industry rank for BioLine Rx's 3-Year RORE % or its related term are showing as below:
FRA:YP2's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -11.485 * Ranked among companies with meaningful 3-Year RORE % only.
BioLine Rx (FRA:YP2) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
BioLine Rx 3-Year RORE % Related Terms
BioLine Rx 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for BioLine Rx's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:YP2 vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, BioLine Rx's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLine Rx 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLine Rx's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where BioLine Rx's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
BioLine Rx (FRA:YP2) has a 3-Year RORE % of 0.00 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on BioLine Rx and its competitors. According to the industry distribution chart, BioLine Rx ranks #999999 out of 1288 companies in the Biotechnology industry.
Is BioLine Rx's 3-Year RORE % too high?
BioLine Rx's current 3-Year RORE % is 0.00. Based on the distribution chart, BioLine Rx ranks #999999 out of 1288 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #999999 out of 1288 companies for 3-Year RORE %. This places BioLine Rx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on BioLine Rx and its competitors. BioLine Rx's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current 3-Year RORE % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score
Get the complete analysis for FRA:YP2
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:YP2 has been successfully added to your 
